Evidence map›Paper›PMID 40346879›Full record

ArticleFundamental & clinical pharmacology2025

ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder.

Abd El Kader Ait Tayeb, Edouard-Jules Laforgue, Benoit Schreck, Marie Grall-Bronnec, Jean-Benoit Hardouin, Juliette Leboucher, OPAL Group, Caroline Victorri-Vigneau, Céline Verstuyft

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fundamental & clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Abd El Kader Ait TayebService de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France.ORCID https://orcid.org/0000-0001-6432-1098
Edouard-Jules LaforgueCHU Nantes, CHU Tours, INSERM, MethodS in Patients-Centered Outcomes and HEalth Research, SPHERE, Nantes Université, Univ Tours, Nantes, 44000, France.ORCID https://orcid.org/0000-0002-7400-1212
Benoit SchreckCHU Nantes, CHU Tours, INSERM, MethodS in Patients-Centered Outcomes and HEalth Research, SPHERE, Nantes Université, Univ Tours, Nantes, 44000, France.
Marie Grall-BronnecCHU Nantes, CHU Tours, INSERM, MethodS in Patients-Centered Outcomes and HEalth Research, SPHERE, Nantes Université, Univ Tours, Nantes, 44000, France.
Jean-Benoit HardouinCHU Nantes, CHU Tours, INSERM, MethodS in Patients-Centered Outcomes and HEalth Research, SPHERE, Nantes Université, Univ Tours, Nantes, 44000, France.
Juliette LeboucherUIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, Nantes, 44000, France.
OPAL Group
Caroline Victorri-VigneauCHU Nantes, CHU Tours, INSERM, MethodS in Patients-Centered Outcomes and HEalth Research, SPHERE, Nantes Université, Univ Tours, Nantes, 44000, France.
Céline VerstuyftService de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France.

Funding

Mission Interministérielle de Lutte contre les Drogues et les Conduites AddictivesUniversité Paris 13
6 · The paper itself

Abstract

backgroundOpioid use disorder (OUD) is an emerging and global public health concern, and its management remains inadequate, notably due to a lack of biomarkers, except for the CYP2B6 genetic polymorphisms.

objectivesHence, the aim of this study was to assess the influence of genetic polymorphisms of ABCB1, SLC22A1, COMT, and OPRM1 on biological parameters and clinical response in patients receiving methadone maintenance treatment (MMT).

methodsA subgroup of 72 patients treated by MMT was genotyped for ABCB1 (rs1045642; rs2032582), SLC22A1 (rs12208357; rs72552763; rs113569197), COMT (rs4680), and OPRM1 (rs1799971) from Opioid PhArmacoLogy (OPAL), a clinical survey of patients suffering from OUD. Associations of these polymorphisms and both clinical and pharmacological (plasma methadone levels) responses were investigated.

resultsAll polymorphisms tested were not associated with (R,S)-methadone concentrations/doses (concentrations relative to doses), (R)-methadone concentrations/doses nor (S)-methadone concentrations/doses in bivariate analyses with codominant and recessive models. Also, polymorphisms tested were not related to clinical response (opiate cessation) during MMT in treated patients. The main limitations of our study were the sample size and the absence of polygenic analyses.

conclusionThis study found no evidence to support the use of genotyping for polymorphisms in the ABCB1, SLC22A1, COMT, and OPRM1 genes in a clinical setting for the management of MMT in OUD.

Indexed as

Catechol O-MethyltransferaseMethadoneOpiate Substitution TreatmentOpioid-Related DisordersOrganic Cation Transporter 1Receptors, Opioid, muAdultAnalgesics, OpioidATP Binding Cassette Transporter, Subfamily BFemaleGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideABCB1 protein, humanAnalgesics, OpioidATP Binding Cassette Transporter, Subfamily BCatechol O-MethyltransferaseCOMT protein, humanMethadoneOPRM1 protein, humanOrganic Cation Transporter 1Receptors, Opioid, mumethadone maintenance treatmentopioid use disorderpharmacodynamic targetspharmacogeneticspharmacokinetic targets

Identifiers

PMID40346879
PMCPMC12065018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.